Skip To Main Content
P. J. Barnes on Muck Rack

P. J. Barnes

As seen in: European Respiratory Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with P. J.

Contact P. J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.

|
By P. J. Barnes, F. L. Lu, H. Faragalla, A. Plotkin
| paperity.org
Current Oncology, Mar 2023 This is a preview of a remote PDF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047249/pdf/ H. Faragalla, A. Plotkin, P. Barnes, F. Lu, Z. Kos, A. Mulligan, A. Bane, Nofech Mozes S.. , Current Oncology, 2023, pp. 3079, Volume 30, Issue 3, DOI: 10.3390/curroncol30030233
Open in Who Shared Issue with article?

Histone acetylation and deacetylation: importance in inflammatory lung diseases

|
By P. J. Barnes, I. M. Adcock, K. Ito
| European Respiratory Journal Verified
Abstract Inflammatory lung diseases are characterised by increased expression of multiple inflammatory genes that are regulated by proinflammatory transcription factors, such as nuclear factor-?B. Gene expression is regulated by acetylation of core histones through the action of coactivators, such as CREB-binding protein, with intrinsic histone acetyltransferase (HAT) activity. Conversely, gene repression is mediated via histone deacetylases (HDACs) and other corepressors.
Open in Who Shared Issue with article?

Global strategy for asthma management and prevention: GINA executive summary

|
By S. S. Hurd, P. J. Barnes, J. Bousquet, E. D. Bateman
| European Respiratory Journal Verified
The patient's current level of asthma control and current treatment determine the selection of pharmacological treatment. For example, if asthma is not controlled by the current treatment regimen, treatment should be stepped up until control is achieved. If control has been maintained for ?3?months, treatment can be stepped down with the aim of establishing the lowest step and dose of treatment that maintains control (Evidence D; see Monitoring to maintain control, later).
Open in Who Shared Issue with article?
See all 6 articles